VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on September 18, 2018, regarding events occurring on September 14, 2018. The filing documents the results of the Company's 2018 Annual Meeting of Stockholders and the disclosure of a new corporate presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance data.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders at the Annual Meeting:
- Election of Directors: Stockholders elected all five nominees to the Board of Directors for a term until the 2019 Annual Meeting. The nominees received the following votes:
- Jon S. Saxe: 4,915,906 For / 97,194 Withheld
- Shawn K. Singh: 4,899,517 For / 113,583 Withheld
- H. Ralph Snodgrass: 4,885,209 For / 127,891 Withheld
- Brian J. Underdown: 4,876,074 For / 137,026 Withheld
- Jerry B. Gin: 4,852,173 For / 160,927 Withheld
- Ratification of Auditors: Stockholders ratified the appointment of OUM & Co, LLP as the independent public accounting firm for the fiscal year ending March 31, 2019. The vote was 15,901,502 For, 902,448 Against, and 208,892 Abstain.
Guidance, Outlook, and Risks
The Company utilized a new corporate presentation at the Annual Meeting, which is attached as Exhibit 99.1. The filing explicitly states that the information in this report and the attached presentation contains forward-looking statements regarding plans, objectives, and expectations. These statements are subject to significant risks and uncertainties and are not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the full content of the Corporate Presentation (Exhibit 99.1) for strategic updates not detailed in this summary.
- Confirm the tenure of the newly elected directors, which extends until the 2019 Annual Meeting.
- Note that OUM & Co, LLP has been ratified as the auditor for the fiscal year ending March 31, 2019.
- Review the definitive proxy statement filed on July 27, 2018, for detailed background on the proposals.